Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)-Reference-Cited by-同舟云学术

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

Published:2020-01-10 Issue:8 Volume:26 Page:1812-1819
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Johnson Douglas B.,Zhao Fengmin,Noel Marcus,Riely Gregory J.,Mitchell Edith P.,Wright John J.,Chen Helen X.^ORCID,Gray Robert J.^ORCID,Li Shuli,McShane Lisa M.^ORCID,Rubinstein Larry V.^ORCID,Patton David,Williams P. Mickey,Hamilton Stanly R.,Conley Barbara A.,Arteaga Carlos L.,Harris Lyndsay N.,O'Dwyer Peter J.,Chen Alice P.^ORCID,Flaherty Keith T.

Funder

NIHNCINCI

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancer;Cancer Medicine;2024-09

2. Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature;Drugs in R&D;2024-08-23

3. Duodenal Fluid Analysis as a Rewarding Approach to Detect Low-Abundance Mutations in Biliopancreatic Cancers;International Journal of Molecular Sciences;2024-08-02

4. The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development;Annals of Oncology;2024-08

5. CDK4/6 and SHP2 mediate BRAF/MEK inhibitor resistance in Class 2 and 3 BRAF mutant cancers;2024-07-29